Every three years the FOPH reviews all pharmaceuticals on the specialities list to check whether they still meet the requirements for inclusion.
Triennial review of pharmaceuticals in 2019
List of pharmaceuticals subject to appeal
The pharmaceuticals which were the object of appeals in the Federal Administrative Court are published in the List of pharmaceuticals subject to an appeal against a decision of the FOPH (see page Information related to the specialities list).
Triennial review of pharmaceuticals in 2018
Complete list of the pharmaceuticals with a reduced price (as reviewed in 2018) and lists of the pharmaceuticals without a price reduction (as reviewed in 2018), subject to possible changes.
Triennial review of drugs in 2017
Complete list of the pharmaceuticals with a reduced price (as reviewed in 2017) and lists of the pharmaceuticals without a price reduction (as reviewed in 2017), subject to possible changes.
Pharmaceuticals are assigned to one of three groups based on the therapeutic group of the specialities list they belong to. Each group is reviewed every three years:
|Group A||Group B||Group C|
Cation exchangers (16)
Gastroenterology, complementary medicine (54)
Metabolism, complementary medicine (57)
Nervous system (01)
Kidneys and water balance (05)
Nervous system, complementary medicine (51)
Kidneys and water balance, complementary medicine (55)
Blood, complementary medicine (56)
Dermatology, complementary medicine (60)
Pulmonary and respiratory (03)
Infectious diseases (08)
Cardiovascular, complementary medicine (52)
Pulmonary and respiratory, complementary medicine (53)
Infectious diseases, complementary medicine (58)
Gynaecology, complementary medicine (59)
Ophthalmology, complementary medicine (61)
Otorhinolaryngology, complementary medicine (62)
Current notifications from the FOPH on the triennial review of inclusion requirements for pharmaceuticals
Information letter dated 22 June 2018 concerning the triennal review 2018 priorities set to ensure timely implementation and differentiated cost shares for drugs and medicinal products in 2018 (PDF, 153 kB, 31.10.2018)
Information letter dated 28 August 2017 concerning the implementation of the differentiated cost share and supplementary information concerning the implementation of the inclusion requirements every three years in 2017 (in German only) (PDF, 195 kB, 01.11.2018)
Last modification 21.08.2019